LAB International Shares Trading on the Frankfurt Stock Exchange
Laval, Quebec (ots/PRNewswire)
LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE), an integrated drug development company focused on the inhalation market, today announced that its shares are available for trading on the Regulated Unofficial Market (Freiverkehr) of the Frankfurt Stock Exchange and on XETRA(R), the Deutsche Borse AG electronic trading system. The inclusion of LAB's securities in the Regulated Unofficial Market is pursuant to an application made by a member-trading firm of the Frankfurt Stock Exchange to assume specialist responsibility for the stock and annual exchange fees.
"We are pleased by the volume generated so far on the Frankfurt Stock Exchange and XETRA(R), which confirms the demand for our shares from European investors. This enhanced exposure and liquidity will benefit all LAB shareholders," said Dr. Halvor Jaeger, CEO of LAB. "With operations in Hungary and Finland, and a European partner for our lead product Fentanyl Taifun(R), we have a significant presence in the European market."
As a company already listed on a recognised Stock Exchange (TSX), there are no obligations or additional disclosure requirements to either the Frankfurt Stock Exchange or German financial supervisory authority resulting from the inclusion on the Freiverkehr.
About LAB International
LAB International (LAB Pharma and LAB Research) is an integrated drug development company. LAB Pharma is focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's approved Taifun(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies. LAB Research is a profitable and growing contract research services division supporting more than 300 clients from state-of-the-art facilities in Canada, the US, and Europe.
LAB's common shares trade on The Toronto Stock Exchange ("TSX")
under the symbol "LAB" with 38.8 million shares outstanding.This news release contains certain forward-looking statements that reflect the current views and/or expectations of LAB International Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
www.labinc.ca
Contact:
For further information: visit LAB's website at www.labinc.ca, or
contact: Luc Mainville, Executive Vice-President, Tel:
+1-(450)-973-2240 ext. 1206, Fax: +1-(450)-973-2259,
mainvillel@labinc.ca; Frederic Dumais, Director, Communication and
Investor Relations, Tel: +1-(450)-973-2240 ext. 1207, Fax:
+1-(450)-973-2259, dumaisf@labinc.ca; James Smith, Investor
Relations, Tel: +1-(416)-815-0700 ext. 229, Fax: +1-(416)-815-0080,
jsmith@equicomgroup.com